S100A9 promotes pulmonary arterial hypertension by regulating mitochondria–endoplasmic reticulum interaction‐mediated inflammatory injury of endothelial cells
Interdisciplinary Medicine · 18.05.2026
DOI: 10.1002/inmd.70142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Interdisciplinary Medicine, online erschienen am 18.05.2026. Verfasst von Chen Gong und 15 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by pulmonary vasoconstriction and remodeling. This study seeks to delineate the role of macrophage‐derived S100 calcium‐binding protein A9 (S100A9) in inducing inflammatory responses mediated by mitochondria‐endoplasmic reticulum (ER) interactions in pulmonary arterial endothelial cells (ECs) during PAH pathogenesis. Both in vivo and in vitro findings consistently revealed that macrophage‐derived S100A9 significantly exacerbated EC injury. Either deletion of S100a9 gene or S100A9 inhibitor restricted pathological progression in PAH mice significantly. S100A9 activates the toll‐like receptor 4 (TLR4)/p38 mitogen‐activated protein kinase (TLR4/p38) pathway in ECs, leading to upregulation of signal‐transducing adaptor protein 2 (STAP2), which subsequently interacts with leucine‐rich repeat kinase 2 to enhance ER‐mitochondrial contact, thereby activating the NOD‐like receptor family pyrin domain containing 3 inflammasome signaling cascade. Targeting STAP2 or inhibiting mitochondria‐ER contact effectively alleviated S100A9‐induced EC injury and PAH progression. This study demonstrates that macrophage‐derived S100A9 promotes pulmonary arterial EC injury via TLR4/STAP2‐mediated mitochondrial–ER interactions, thereby exacerbating PAH progression. Genetic or molecular interventions targeting S100A9 exhibit promising therapeutic potential for ameliorating PAH.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
Zitieren
APA
Gong, C., Chen, L., Zhao, Y., Wang, X., Yuan, Q., Fang, X., Li, L., Xu, Y., Jiang, S., Xu, G., Meng, K., Wang, D., Cao, K., Sheng, J., Guo, L., & Shen, S. (2026). S100A9 promotes pulmonary arterial hypertension by regulating mitochondria–endoplasmic reticulum interaction‐mediated inflammatory injury of endothelial cells. Interdisciplinary Medicine. https://doi.org/10.1002/inmd.70142
Vancouver
Gong C, Chen L, Zhao Y, Wang X, Yuan Q, Fang X, et al. S100A9 promotes pulmonary arterial hypertension by regulating mitochondria–endoplasmic reticulum interaction‐mediated inflammatory injury of endothelial cells. Interdisciplinary Medicine. 2026. doi:10.1002/inmd.70142
BibTeX
@article{Gong2026,
author = {Gong, Chen and Chen, Long and Zhao, Yiting and Wang, Xiaohe and Yuan, Qiang and Fang, Xiaofeng and Li, Liuyi and Xu, Yinbo and Jiang, Shumei and Xu, Guangwen and Meng, Ke and Wang, Delong and Cao, Kangli and Sheng, Jianlong and Guo, Liling and Shen, Shichun},
title = {S100A9 promotes pulmonary arterial hypertension by regulating mitochondria–endoplasmic reticulum interaction‐mediated inflammatory injury of endothelial cells},
journal = {Interdisciplinary Medicine},
year = {2026},
doi = {10.1002/inmd.70142}
}
EUVIMED